Christoph Klade

2.7k total citations
51 papers, 1.6k citations indexed

About

Christoph Klade is a scholar working on Genetics, Rheumatology and Hepatology. According to data from OpenAlex, Christoph Klade has authored 51 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Genetics, 18 papers in Rheumatology and 14 papers in Hepatology. Recurrent topics in Christoph Klade's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (20 papers), Eosinophilic Disorders and Syndromes (15 papers) and Hepatitis C virus research (14 papers). Christoph Klade is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (20 papers), Eosinophilic Disorders and Syndromes (15 papers) and Hepatitis C virus research (14 papers). Christoph Klade collaborates with scholars based in Austria, Germany and France. Christoph Klade's co-authors include Erich Tauber, Elisabeth Schuller, Bernd Jilma, Vera Buerger, Michael P. Manns, Heiner Wedemeyer, Christa Firbas, Sandra Jelovcan, Günther R. Adolf and E. Krystek and has published in prestigious journals such as Blood, Gastroenterology and Journal of Virology.

In The Last Decade

Christoph Klade

49 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christoph Klade Austria 23 513 470 450 387 385 51 1.6k
Fabiana Falugi Italy 20 988 1.9× 950 2.0× 1.4k 3.2× 791 2.0× 1.5k 3.9× 25 3.5k
Sandra Nuti Italy 27 556 1.1× 325 0.7× 1.1k 2.4× 119 0.3× 865 2.2× 54 3.2k
Roberto Petracca Italy 19 678 1.3× 293 0.6× 1.5k 3.4× 113 0.3× 1.5k 3.9× 33 3.9k
M. Sumiya United Kingdom 13 295 0.6× 197 0.4× 417 0.9× 176 0.5× 67 0.2× 17 1.9k
Vanitha S. Raman United States 18 355 0.7× 187 0.4× 561 1.2× 661 1.7× 39 0.1× 22 2.0k
Nadia L. Bernasconi United States 9 252 0.5× 305 0.6× 721 1.6× 239 0.6× 49 0.1× 9 2.3k
Heribert Stoiber Austria 36 570 1.1× 894 1.9× 921 2.0× 240 0.6× 70 0.2× 119 3.6k
Stirling Edwards Australia 20 287 0.6× 112 0.2× 301 0.7× 390 1.0× 107 0.3× 34 1.2k
Isabelle Staropoli France 21 466 0.9× 771 1.6× 284 0.6× 402 1.0× 170 0.4× 37 2.0k
Giulietta Saletti Germany 17 237 0.5× 394 0.8× 514 1.1× 53 0.1× 334 0.9× 30 1.4k

Countries citing papers authored by Christoph Klade

Since Specialization
Citations

This map shows the geographic impact of Christoph Klade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoph Klade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoph Klade more than expected).

Fields of papers citing papers by Christoph Klade

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christoph Klade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoph Klade. The network helps show where Christoph Klade may publish in the future.

Co-authorship network of co-authors of Christoph Klade

This figure shows the co-authorship network connecting the top 25 collaborators of Christoph Klade. A scholar is included among the top collaborators of Christoph Klade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christoph Klade. Christoph Klade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Barbui, Tiziano, Arianna Ghirardi, Victoria Empson, et al.. (2025). Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera. Blood Cancer Journal. 15(1). 132–132. 2 indexed citations
2.
3.
Farr, Clemens V., Ali El‐Kasaby, Walter Sandtner, et al.. (2024). Probing the Chemical Space of Guanidino-Carboxylic Acids to Identify the First Blockers of the Creatine-Transporter-1. Molecular Pharmacology. 106(6). 319–333.
4.
Petrides, Petro E., Christian Schoergenhofer, Rudolf Widmann, Bernd Jilma, & Christoph Klade. (2017). Pharmacokinetics of a Novel Anagrelide Extended‐Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product. Clinical Pharmacology in Drug Development. 7(2). 123–131. 4 indexed citations
5.
Klade, Christoph, Elisabeth Schuller, Thomas Boehm, Alexander von Gabain, & Michael P. Manns. (2012). Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination. Vaccine. 30(19). 2943–2950. 22 indexed citations
6.
Gessel, Yvonne Van, Christoph Klade, Robert Putnak, et al.. (2011). Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO®) induced neutralizing antibody titers. Vaccine. 29(35). 5925–5931. 83 indexed citations
7.
Eder, Susanne, Katrin Dubischar-Kastner, Christa Firbas, et al.. (2011). Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51. Vaccine. 29(14). 2607–2612. 47 indexed citations
8.
Dubischar-Kastner, Katrin, Susanne Eder, Tomáš Jelı́nek, et al.. (2010). Long term immunogenicity following a booster dose of the inactivated Japanese encephalitis vaccine IXIARO®, IC51. International Journal of Infectious Diseases. 14. e449–e449. 1 indexed citations
9.
Firbas, Christa, Thomas Boehm, Vera Buerger, et al.. (2010). Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. Vaccine. 28(12). 2397–2407. 45 indexed citations
10.
Dubischar-Kastner, Katrin, Susanne Eder, Vera Buerger, et al.. (2010). Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO®, IC51. Vaccine. 28(32). 5197–5202. 45 indexed citations
11.
Dubischar-Kastner, Katrin, et al.. (2009). Immunogenicity and safety of IXIARO® (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine. 28(3). 834–839. 44 indexed citations
12.
Wedemeyer, Heiner, Elisabeth Schuller, Verena Schlaphoff, et al.. (2009). Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine. 27(37). 5142–5151. 58 indexed citations
13.
Klade, Christoph, Rudolf Stauber, Manuela Meyer, et al.. (2009). Hepatitis C virus-specific T cell responses against conserved regions in recovered patients. Vaccine. 27(23). 3099–3108. 7 indexed citations
14.
15.
16.
Schuller, Elisabeth, Bernd Jilma, Georg Golor, et al.. (2008). Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51. Vaccine. 26(34). 4382–4386. 58 indexed citations
17.
Klade, Christoph, Heiner Wedemeyer, Thomas Berg, et al.. (2008). Therapeutic Vaccination of Chronic Hepatitis C Nonresponder Patients With the Peptide Vaccine IC41. Gastroenterology. 134(5). 1385–1395.e1. 123 indexed citations
18.
Fytili, Paraskevi, Verena Schlaphoff, Christoph Sarrazin, et al.. (2008). Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. Vaccine. 26(31). 3818–3826. 38 indexed citations
19.
Nagy, Eszter, Martin Blüggel, Helmut E. Meyer, et al.. (2002). Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis. PROTEOMICS. 2(5). 580–590. 131 indexed citations
20.
Klade, Christoph, Tilman Voss, E. Krystek, et al.. (2001). Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. PROTEOMICS. 1(7). 890–898. 158 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fabiana Falugi Breakdown of academic impact, for papers by Sandra Nuti Breakdown of academic impact, for papers by Roberto Petracca Breakdown of academic impact, for papers by M. Sumiya Breakdown of academic impact, for papers by Vanitha S. Raman Breakdown of academic impact, for papers by Nadia L. Bernasconi Breakdown of academic impact, for papers by Heribert Stoiber Breakdown of academic impact, for papers by Stirling Edwards Breakdown of academic impact, for papers by Isabelle Staropoli Breakdown of academic impact, for papers by Giulietta Saletti
Rankless by CCL
2026